Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
| 59.40 Delayed Data As of 3:59pm ET |  -1.30 / -2.14%Today’s Change | 19.88 Today|||52-Week Range 71.11 | -4.56% Year-to-Date |
Latest DCPH News | Press Releases
| FDA Approval Could Be a Game-Changer for Deciphera Pharmaceuticals May 23 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 60.70 |
| Today’s open | 60.02 |
| Day’s range | 56.05 - 60.35 |
| Volume | 30,783 |
| Average volume (3 months) | 575,586 |
| Market cap | $3.3B |
Data as of 3:59pm ET, 06/02/2020
Growth & Valuation
| Earnings growth (last year) | -58.95% |
| Earnings growth (this year) | -25.18% |
| Earnings growth (next 5 years) | +21.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 106.73 |
| Price/Book | 5.53 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ARWRArrowhead Pharmaceut... | -0.52 | -1.56% |
| HALOHalozyme Therapeutic... | +0.08 | +0.33% |
| BPMCBlueprint Medicines ... | +4.44 | +6.70% |
| MNTAMomenta Pharmaceutic... | -0.31 | -1.00% |
Data as of 4:00pm ET, 06/02/2020
Financials
| Next reporting date | August 11, 2020 |
| EPS forecast (this quarter) | -$1.37 |
| Annual revenue (last year) | $25.0M |
| Annual profit (last year) | -$192.3M |
| Net profit margin | -769.02% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
